Lake Forest, CA (October 27, 2017) - Rubicon Biotechnology, LLC is pleased to announce that it was awarded a SBIR Phase I grant by the National Eye Institute titled “Targeted Hsp72 as a Therapeutic for Central Retinal Artery Occlusion”. Rubicon is collaborating with Drs. Michael Gorin and Anna Matynia and their teams at the Stein…
Read more
Rubicon Announces Publication in JACC
Lake Forest, CA (September 25, 2017) - Rubicon Biotechnology, LLC announces the publication of preclinical results for our lead platform technology, Fv-Hsp72, for the treatment of stress injuries caused by a myocardial infarction. The article titled “Cardioprotective effects of HSP72 administration on ischemia-reperfusion injury", by collaborators from Rubicon and the laboratory of Jagat Narula, MD, PhD,…
Read more
Rubicon Announces Heat Shock Protein Publication
Lake Forest, CA (September 16, 2016) - Rubicon Biotechnology, LLC announces the publication of a review article called "Targeted Heat Shock Protein 72 for Cytoprotection" by Dr. Missag Parseghian, Chief Scientific Officer of Rubicon, in the Annals of the New York Academy of Sciences.Dr. Stephen Hobson of Seacoast Scientific, Inc. and Richard Richieri, COO of Rubicon…
Read more